ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer
Optimum Strategic Communications is delighted to announce that ISA Pharmaceutical’s Chief Scientific Officer and Founder, Professor Dr. Cornelis “Kees” Melief has been nominated and selected by the Board of Directors of the Society for Immunotherapy of Cancer (SITC) as a Fellow of the Academy of Immuno-Oncology (FAIO).
Professor Melief is a globally recognised immunology expert, specialising in cancer immunology and immunotherapy, known for his groundbreaking translational work in devising new cancer therapies that activate the patient’s own immune system. In addition to his role as Chief Scientific Officer at ISA Pharmaceuticals, he is Emeritus Professor of Immunology at the Leiden University Medical Center in the Netherlands. He is the author of more than 545 peer-reviewed publications, cited over 67,000 times, and the inventor on more than 30 patents and patent applications.
The fellowship recognises Prof. Melief’s inspiring contributions and dedication to cancer immunotherapy and will be presented at the SITC’s 37th Annual Meeting in Boston, 8-12 November 2022.
